Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
RIC Allograft in Older People with B-Cell ALL
Am J Hematol; ePub 2016 Nov 12; Rosko, et al
Reduced intensity conditioning hematopoietic cell transplant (RIC HCT) offers promising overall survival and acceptable nonrelapse mortality in older people with B-cell acute lymphoblastic leukemia, according to a study involving 273 individuals.
Investigators assessed participants who underwent RIC HCT between 2001 and 2012 using mostly unrelated (59%) or HLA-matched sibling (32%) donors. Among the results:
- 3-year cumulative incidence of nonrelapse mortality was 25%; relapse rate was 47%.
- 3-year overall survival rate was 38%.
- Relapse was the leading cause of mortality, accounting for ~half of all deaths.
- 3-year risk of nonrelapse mortality was 34% when Karnofsky performance status was <90; it was 18% when it was ≥90.
- Mortality rate was 50% higher in patients who were ≥66 years of age than it was in those between the ages of 55 and 60.
- Mortality rate was twice as high in those with advanced disease.
Citation:
Rosko A, Wang H, de Lima M, et al. Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. [Published online ahead of print November 12, 2016]. Am J Hematol. doi:10.1002/ajh.24575.